Key facts
- This page summarizes Douglas Doerfler's Form 4 filing for MAXCYTE, INC. (MXCT).
- 6 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 06 Dec 2023, 16:15.
Douglas Doerfler - 04 Dec 2023 Form 4 Insider Report for MAXCYTE, INC. (MXCT)
- Reporting relationship
- President and CEO, Director
- Issuer ticker
- MXCT
- Reported as of
- 04 Dec 2023
- Net transaction value
- -$634,427
- SEC form
- 4
- Accepted by SEC
- 06 Dec 2023, 16:15:49 UTC
- Prior SEC filing
- 01 Dec 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Brian F. Leaf, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas Doerfler filed Form 4 for MAXCYTE, INC. (MXCT) on 06 Dec 2023.
Change
- Previous filing in this sequence was filed on 01 Dec 2023.
- Current net transaction value: -$634,427.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MXCT
transaction
Common Stock
Options Exercise
- Transaction value
- $1,000
- Shares
- +25,008
- Change %
- +7.5%
- Price
- $0.0400*
- Shares after
- 358,205
- Date
- 04 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
MXCT
transaction
Common Stock
Sale
- Transaction value
- $125,290
- Shares
- -25,008
- Change %
- -7%
- Price
- $5.01
- Shares after
- 333,197
- Date
- 04 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F2
MXCT
transaction
Common Stock
Options Exercise
- Transaction value
- $3,978
- Shares
- +99,442
- Change %
- +30%
- Price
- $0.0400*
- Shares after
- 432,639
- Date
- 05 Dec 2023
- Ownership
- Direct
- Footnotes
- F1
MXCT
transaction
Common Stock
Sale
- Transaction value
- $514,115
- Shares
- -99,442
- Change %
- -23%
- Price
- $5.17
- Shares after
- 333,197
- Date
- 05 Dec 2023
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MXCT
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -25,008
- Change %
- -12%
- Price
- $0.000000
- Shares after
- 184,522
- Date
- 04 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,008
- Exercise price
- $0.0400
- Footnotes
- F1, F4
MXCT
transaction
Derivative
Employee Stock Option (right to buy)
Options Exercise
- Transaction value
- $0
- Shares
- -99,442
- Change %
- -54%
- Price
- $0.000000
- Shares after
- 85,080
- Date
- 05 Dec 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 99,442
- Exercise price
- $0.0400
- Footnotes
- F1, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
Footnote F2
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.27, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F4
This option is fully vested and exercisable.